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Background: Wound healing involves complex mechanisms, which, if properly chaperoned, can enhance patient
recovery. The abilities of platelets and keratinocytes may be harnessed in order to stimulate wound healing through
the formation of platelet clots, the release of several growth factors and cytokines, and cell proliferation. The aim of
the study was to test whether autologous keratinocyte suspensions in platelet concentrate would improve wound
healing. The study was conducted at the Lausanne University Hospital, Switzerland in 45 patients, randomized to
three different topical treatment groups: standard treatment serving as control, autologous platelet concentrate (PC)
and keratinocytes suspended in autologous platelet concentrate (PC + K). Split thickness skin graft donor sites were
chosen on the anterolateral thighs of patients undergoing plastic surgery for a variety of defects. Wound healing
was assessed by the duration and quality of the healing process. Pain intensity was evaluated at day five.
Results: Healing time was reduced from 13.9 ± 0.5 days (mean ± SEM) in the control group to 7.2 ± 0.2 days in the
PC group (P < 0.01). An addition of keratinocytes in suspension further reduced the healing time to 5.7 ± 0.2 days.
Pain was reduced in both the PC and PC + K groups. Data showed a statistically detectable advantage of using PC + K
over PC alone (P < 0.01).
Conclusion: The results demonstrate the positive contribution of autologous platelets combined with keratinocytes in
stimulating wound healing and reducing pain. This strikingly simple approach could have a significant impact on
patient care, especially critically burned victims for whom time is of the essence.
Clinical trial registry information: Protocol Record Identification Number: 132/03
Registry URL: http://www.clinicaltrials.govBackground
Despite the progress achieved in the past few decades,
wound healing remains a difficult issue to which modern
medicine does not always have an efficient response.
The surgical treatment of wounds focuses primarily on
accelerating the healing process and overcoming the ini-
tial danger and deleterious consequences associated with* Correspondence: Wassim.Raffoul@chuv.ch
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reproduction in any medium, provided the orbleeding and infection. However, under certain circum-
stances, surgery is not an option. As such, methods like
hemotherapy, which consists of applying dressings
soaked in blood to the wound itself, have been applied
in order to accelerate the healing of certain difficult
wounds. Physicians who used this treatment were un-
aware that they were in fact treating wounds with
growth factors [1,2].
In recent years, new treatments focusing on dressing
design and composition have been suggested to acceler-
ate wound healing. The ideal dressing should be easy toLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Patient population characteristics
Group Control PC PC + K
(n = 15) (n = 15) (n = 15)
Age in years,
mean ± SEM
(median)
42.5 ± 3.1 (39) 45.5 ± 3.9 (48) 46.9 ± 5.3 (54)
Gender, M : F 11 : 4 9 : 6 5 : 10
Diagnosis, number (%)
Trauma 7 (47) 3 (20) 3 (20)
Burn 2 (13) 6 (40) 4 (27)
Ulcer 2 (13) 1 (7) 3 (20)
Cutaneous tumors 0 (0) 4 (27) 0 (0)
Others 4 (27) 1 (7) 5 (33)
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local pain and permit a pain-free dressing replacement
[3,4]. Affordability is also an important factor. Novel
‘smart’ dressings have indeed been designed to cover
graft donor sites and stimulate their healing time. How-
ever, none satisfies all the criteria mentioned above,
hence the importance of researching other tools. Specific
growth factors such as platelet-derived growth factor
(PDGF), epidermal growth factor (EGF) and fibroblast
growth factor (FGF) have been used in topical treat-
ments [5] but results published thus far are inconclusive,
probably because of the complexity of the healing
phenomenon which cannot be stimulated by the local
application of one factor at any given time, especially
since the dosages are often well above physiological
levels. Indeed, the orchestrated release of growth factors
must be respected in order to best emulate the physio-
logical process [6-8]. Therefore, even with increased pre-
cision in surgical technique, post-operative smart
dressings, administration of growth factors and regular
use of nutritional supplements, reported healing time
and risk of complications remained unchanged [9,10],
resulting in inconsistent and disappointing outcomes
with dissuasive treatment costs.
Platelets play a fundamental role in wound healing,
primarily through the formation of platelet clots and the
release of many growth factors and cytokines [5]. It has
also been shown that epidermal keratinocytes play an
essential role in wound healing [11-17]. Keratinocytes,
when applied to a wound, should theoretically induce
and stimulate healing by releasing growth factors or
multiplying in situ [18], thereby enhancing the healing
effect of blood platelets. Theoretically, it is possible to
amplify the effects of the first steps of the wound healing
cascade by increasing the local concentration of platelets
and keratinocytes which would then induce an increased
production of trophic and growth factors [19-23].
A prospective randomized study with three groups of
patients was performed in order to test whether a plate-
let concentrate or keratinocytes suspended in a platelet
concentrate could enhance wound healing. One experi-
mental group was treated with an autologous platelet
concentrate, another experimental group received a sus-
pension of autologous keratinocytes combined with a
platelet concentrate while a standard treatment was ad-
ministered to patients in the control group.
Methods
Study design
The clinical study was conducted as a prospective, ran-
domized controlled, blinded phase I trial (Protocol Rec-
ord 132/03; http://www.clinicaltrials.gov). After approval
by the institutional ethics committee and the Swiss
agency for therapeutic products (Swissmedic), 45 pa-tients aged between 18 and 80 years and presenting graft
donor sites not exceeding 15% of their total body surface
were enrolled in the study between June 2005 and
March 2006 at the Lausanne University Hospital in
Switzerland. Each collected skin graft was 0.2 mm in
thickness, located on the anterolateral region of the
thigh and corresponding to a mean area of 180cm2
(range 25 to 200 cm2). Skin grafts were collected by
means of a dermatome (Aesculap AG, Tuttlingen,
Germany) with a thickness of 0.2 mm, which is the
standard in our department in burn patients in order to
achieve healing. In order to create comparable wounds,
we used the same protocol in all patients. Exclusion cri-
teria were: treatment with immunosuppressors or corti-
coids, terminal renal insufficiency and severe peripheral
arteriopathy. Patients were randomized to one of three
groups of 15 patients: control, platelet concentrate (PC)
and platelet concentrate with keratinocytes (PC + K)
(Table 1). Block randomization was generated using a
computer program (S-Plus 4.0 for Windows, Microsoft
Schweiz, Richtistrasse 3, 8304 Wallisellen (Zurich),
Switzerland) by an investigator with no clinical involve-
ment in the trial. Allocation was concealed from patients
and observers.
Platelet isolation
At the initiation of surgery, an 8.5 cc blood sample was
collected from a vein in the upper arm without IV perfu-
sion by means of a RegenKit® (RegenLab, En Budron B2,
1052 Le Mont-sur-Lausanne, Switzerland). The blood
sample tube was immediately centrifuged for eight mi-
nutes at 2,800 rpm leading to a separation of the red
cells from the plasma. Under these conditions, the plate-
lets formed a narrow white band at the interface be-
tween the red cells and the plasma. After resuspending
the platelets in the plasma by gentle agitation, the
resulting platelet concentrate was transferred to another
sterile tube and placed at 37°C. The final volume of
platelet concentrate ranged between 3.5 and 4.5 ml. PC
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isolated mononuclear cells were observed
Autologous keratinocyte isolation
A sample of 0.2 mm thick skin collected by means of a
dermatome was placed in a transport tube containing
20 ml of DMEM, 102 U/ml of penicillin and 0.1 mg/ml
of streptomycin sulfate. The skin sample was sent along
with the platelet concentrate to our cell culture labora-
tory. After being rinsed three times with an isotonic PBS
solution, the skin sample was cut into small fragments
(approximately 1 mm2) with a scalpel and digested in a
0.05% trypsin - 0.01% EDTA mixture for 45 minutes at
37°C. The supernatant containing the keratinocytes was
centrifuged for three min at 200 g and the resulting cell
pellet was washed twice in DMEM solution. The cells
were then counted under the microscope. Finally, the
cell pellet was suspended in 3.5 to 4.5 ml of autologous
platelet concentrate. All procedures were conducted
under a laminar flow, following strict rules of asepsis
and sterility in a cell processing center, according to the
GMP procedures.
Surgical treatment
After collecting skin grafts, all donor sites were tempor-
arily covered with gauze impregnated with an adrenaline
solution (2 mg/L in saline). At the end of the surgical
intervention, the PC group received a platelet concen-
trate obtained using the procedure described above. A
spray applicator consisting of two syringes maintained at
37°C, one containing PC (10 volume) and the other a
10% calcium chloride solution (1 volume), was used to
dispense the mixture on to the wound bed. The mix-
tures were left to coagulate in situ before applying any
dressings. Mean cell counts in suspension for 4 ml were
2,300 × 106 platelets and 22.6 × 106 keratinocytes. Aver-
age counts on wounds were 13.5 × 106/cm2 platelets and
80,000 keratinocytes/cm2 respectively. The PC + K group
received a suspension of keratinocytes in PC following a
similar procedure. Wounds from all groups were then
covered with three layers of paraffin gauze (Jelonet®,
Smith & Nephew, 15 Adam Street, London WC2N 6LA,
UK), wrapped with standard bandages (Kerlix®, Covidien,
15 Hampshire Street, Mansfield, Ma) and contained in
an elastic bandage. Control wounds were covered by
three layers of paraffin gauze and bandages (the standard
treatment for skin graft take in our department). All pa-
tients and observers were blinded to the treatment.
Wound healing
Treatment efficiency was evaluated with respect to the
duration (in days) until complete healing occurred along
with assessments of the degree of epithelialization. The
first evaluation was done on post-operative day five byan observer blinded to the type of treatment. The dress-
ing and bandages were replaced with sheets of paraffin
gauze and covered with standard dry dressings. Subse-
quent evaluations were done at two-day intervals until
complete healing. Time until complete wound healing
was recorded. Local pain, in general and specifically
while replacing dressings, was evaluated by the patients
on post-operative day five using a visual analogical scale
with 0 representing no pain and 10 representing extreme
pain. Both pre-operative and post-operative pictures
documenting wound healing progression were also
taken. Eventual adverse effects were to be recorded
throughout the follow-up.Statistical analysis
Results are expressed as mean ± SEM. One-way ANOVA
and post hoc Tukey’s tests were used to confirm sta-
tistically detectable differences between groups with
P-values below 0.05. The statistical package was JMP®
(Version 5.5, SAS Institute Inc., Cary, NC, USA).Results
Altogether, 45 patients were included (Table 1). There
were no statistically significant differences between the
groups with respect to gender and age despite the PC +K
group having a ratio of female to male patients which was
almost the inverse of that in other groups. The four most
frequent pathologies in our groups were traumatic defects,
burns, ulcer of venous etiology and cutaneous tumors. In
the control group, the other categories consisted of one
lumbar hemolymphangioma, one equinous deformity with
neurinoma, one excision of a thigh sarcoma and one de-
fect after total knee arthroplasty. In the PC group, there
was only one patient outside the aforementioned categor-
ies. This case was a carcinoma of the rectum needing skin
graft after perineal reconstruction. In the PC +K group,
there were five patients not belonging to the main categor-
ies. These consisted of one hidradenitis suppurativa, one
thigh sarcoma, one necrotizing pancreatitis, one ankle os-
teitis with secondary flap reconstruction and one keloid
excision.
Wound healing was significantly shortened in PC and
PC + K groups compared to control (P < 0.01), reflecting
the stimulation of wound healing by the platelet concen-
trate (Figure 1A). In the PC group, wound healing time
was reduced to 7.2 ± 0.2 days compared with 13.9 ± 0.5
days in the control. A further significant reduction of
the healing time was observed in the PC + K group com-
pared to the PC group (P < 0.01). Indeed, the PC + K
group showed the fastest wound healing, averaging 5.7 ±
0.2 days (Figure 2).
Patients from the PC group also experienced a signifi-
cant reduction of the pain resulting from the skin graft
Ti
m
e 
to
 w
ou
nd
 h
ea
lin
g 
(d
ay
s)
 
5
10
15
20
p<0.01
p<0.01
Pa
in
 (V
A
S)
 D
ay
 5
0
2
4
6
8
10
Control PC PC+K
p<0.01
P<0.01
A
B
Figure 1 Results show a significant reduction in time to wound
healing associated with less pain. (A) Duration in days until
complete wound healing. (B) Pain intensity reported on post-
operative day five using a visual analogical scale. Data as box plots
(sample minimum, lower quartile, median and upper quartile as well
as sample maximum).
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ther enhanced in the PC + K group (Figure 1B).
No infection was noted. The tolerance and acceptance
of the treatments were excellent and no undesirable ef-
fects were noted.
Discussion
Studying clinical wound healing is challenging because
of an inherently high variability, which may alter the
evaluation of results. The principal differences lie within
the wound itself, specifically its depth, localization, eti-
ology and other associated pathologies [24]. This moti-
vated our aim to evaluate skin graft donor sites rather
than the grafted areas in an attempt to minimize inher-
ent differences between wounds. Indeed, a skin graft re-
mains the most used technique for wound closure
[25,26] and the surgical technique has been refined over
the years due to improvement of the apparatus used to
take skin grafts. This now allows for an increased preci-
sion and reproducibility. For this reason and due to the
relative ease of monitoring donor sites, this type of
wound has become the ideal model to study wound
healing in vivo [26]. Healing of the donor site, however,
may vary and depends on both the depth of the woundand its surface area which may range from a few square
centimeters to several hundred. The energy cost of
healing is elevated and aggravated by losses of minerals,
trace elements, proteins and fluids [25,26]. This becomes
particularly important when extensive surfaces are in-
volved, as in the case of major burns, major trauma, and
in children and elderly patients. In those cases, new
large wounds appear at skin graft donor sites, with an el-
evated risk of complication such as infections and de-
layed healing which further increases the toll on the
body. It is therefore, extremely important to attempt to
stimulate and accelerate donor site wound healing [27].
Under normal circumstances, and according to the in-
clusion criteria we defined, the graft donor sites investi-
gated in this study should heal spontaneously within 12
to 14 days. Encouraging results were obtained while
assessing the healing effect of the application of an au-
tologous platelet concentrate alone and the application
of a keratinocyte suspension combined with an autolo-
gous platelet concentrate to the donor site compared to
a standard treatment. Indeed, clinical efficacy was not-
ably enhanced as experimental groups showed an
important reduction of healing time, particularly in the
PC + K group which only required an average of five
days, less than half the time required by conventional
methods (Figure 1A). These results show the ability of
concentrated platelets and keratinocytes to amplify and
enhance the first phases of the healing cascade. In our
trial, we didn’t include a group of patients receiving
keratinocytes only, because previous work has already
demonstrated its benefit on wound healing [28-31] and
because our purpose was to verify the use of PC as a
transport medium for keratinocytes.
Our study also confirms that platelet concentrates may
be successfully obtained through a one-step isolation
procedure. The protocols used in this study however,
may of course be further optimized. For instance, al-
though the platelet concentrates were prepared during
the surgical intervention, it may be possible to do so on
the eve of the operation, thereby effectively reducing the
workload in the operating room. Similarly, we are cur-
rently investigating ways to further simplify methods of
obtaining cutaneous cell suspensions and to better
understand their contribution to enhancing the healing
cascade and their interaction with the delivered platelets.
Different types of dressings such as hydrocellular,
hydrocolloid, alginates and paraffin gauze have been
tested in our department during the past few years in an
attempt to reduce pain. Although subsiding with the use
of some hydrocellular dressings, pain and discomfort
almost always remained a problem during dressing re-
placement which is done imperatively in the first 48
hours and a week following the procedure [3,9,32]. The
elevated cost per unit of the above mentioned dressing
Figure 2 Pictures demonstrate greater amount of epithelialization when treated with platelet concentrate or keratinocytes suspended
in a platelet concentrate. (A) and (B) show treatment with PC at operation time (left panel) and seven days later (right panel). (C) and (D) show
treatment with PC + K at operation time (left panel) and five days later (right panel).
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surface to be covered [9,33,34].
The study shows significant pain reduction when using
PC alone, and an even more pronounced reduction using
the combination of PC with keratinocytes (Figure 1B). The
effect was virtually immediate and long lasting andwithout the need for repeated application. Some patients
who had previously healed skin graft donor site wounds
noted the difference in treatment and found the recovery
relatively pain free. This admittedly unforeseen observa-
tion could be partially explained by the ability of the plate-
let gel to maintain a humid environment around the
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hydrofibers and hydrocolloids), however, attempt to gene-
rate that same effect although the pain does not disappear
completely and is usually only attenuated, hinting that
there may be more to the story. Indeed, platelets may be
releasing or stimulating the release of substances with an
analgesic effect. As shown previously [35], platelets are
known to release endorphins, which may explain why the
analgesic effect observed was rapid and long lasting. We
have noted the same observation in patients presenting
chronic wounds and treated with platelet gels (data not
shown). Specific studies must be conducted to explain pre-
cisely how the platelet concentrates act directly or indir-
ectly on pain in acute wounds and how keratinocytes may
further enhance that effect, as we have seen in this study.
The risk of wound infection is directly related to the
healing time, while delayed wound healing may in cer-
tain cases be the only sign of infection [9,10,36-38]. This
can be explained by the bacterial release of endotoxins
that increase pro-inflammatory cytokines such as Il-1
and TNF-α, thereby causing increased levels of
metalloproteinases (MMPs) and a decrease in the pro-
duction of growth factors [36]. Additionally, wound in-
fections increase exudates and pain and are associated
with increased patient discomfort, an unesthetic scar
and an important increase in the cost of care. As such,
infection of the donor site may sometimes expand, espe-
cially in debilitated, malnourished, polytraumatized pa-
tients, major burn victims or patients treated with drugs
that render the skin fragile, such as corticoids. Ranging
from cellulitis to septicemia, complications may very
well threaten the patient’s survival.
No infectious complication was observed in this study.
This can be explained by the acceleration of healing and
the potential antibacterial role of platelets and white
blood cells trapped in the platelet concentrate [39,40].
Additional studies may shed some light onto the mecha-
nisms underlying this effect and whether platelets act
directly to prevent infections or through the stimulation
or other cells. Whether cutaneous cell suspensions help
enhance this effect would also be of interest, especially
in the case of chronic wounds.
The methods presented here benefit from an import-
ant advantage in that no heterologous product was used.
PC can be obtained by simple centrifugation with a
Conformité Européenne (CE) approved device. This
study also demonstrates that platelet concentrate may be
an excellent vehicle for transporting a suspension of au-
tologous keratinocytes onto a wound. Keratinocytes,
which play an essential role in wound healing thanks to
their multiplicative capacity and their metabolic role
[11-17], effectively enhance the effect of PC, an observa-
tion which opens the door to a much larger range of ap-
plications involving the addition of other cell types suchas fibroblasts, which also play an important role in
wound healing [7]. In the case of major burns, every day
gained in terms of healing translates into increased
chances of survival, reduced suffering, reduced scar ran-
som and an important decrease in what is usually a
major cost to health institutions. The preparation of a
PC requires a cell processing unit and qualified
personnel for cell isolation. The laboratory procedure
takes approximately 90 minutes. Taking into account the
personnel salary and the kit for platelet isolation, the
cost of a PC + keratinocyte preparation may be estimated
between 300 to 500 Swiss Francs. There is no major ma-
nipulation of the tissue, including cell culture and ex-
pansion. As only enzymatic treatment and centrifugation
steps are needed, tissue can be rapidly processed in a
Class A laminar flow system dedicated for this activity.
Conclusion
The data show that platelet concentrates have a bene-
ficial effect on wound healing and can be used to de-
liver keratinocytes to the wounds. The association of
platelet concentrates and keratinocytes appears to be
the most efficient way to enhance wound healing. We
believe that this method could be the first line treat-
ment for patients with impaired healing. However, the
complexity and cost of the method have to be re-
duced in order for this technique to be used as a
standard protocol.
This study showed beneficial effects regarding pain
and time to complete wound healing. This procedure
opens the path towards a more efficient treatment of
chronic wounds such as ulcers, including decubitus
ulcers and those related to diabetic neuropathies or
necrotic angiodermatitis. It also provides undeniable
advantages in treating major burn victims. Future tri-
als are required to address the question of the spe-
cific impact of keratinocytes on wound healing.Consent
Written informed consent was obtained from the patient
for publication of this report and any accompanying
images.
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